PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients
Marzia Del Re, Stefania Crucitta, Giulia Lorenzini, Claudia De Angelis, Lucrezia Diodati, Diletta Cavallero, Irene Bargagna, Paola Cinacchi, Beatrice Fratini, B. Salvadori, Matteo Ghilli, Manuela Roncella, Andrea Fontana, Romano Danesi, Federico Cucchiara
Topics & Concepts
Internal medicineMedicineOncologyLiquid biopsyBreast cancerMutationCancerPI3K/AKT/mTOR pathwayCancer researchGastroenterologyBiologyGeneGeneticsApoptosisAdvanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancerPARP inhibition in cancer therapy